Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.
暂无分享,去创建一个
J. Goldman | S. Marley | M. Gordon | I. Bellantuono | H. Stauss | Liquan Gao | L. Gao | A. Elsässer | S. Marley | Liquan Gao | Annika Elsässer
[1] J. Goldman,et al. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. , 1999, Experimental hematology.
[2] H. Stauss,et al. Immunotherapy with CTLs restricted by nonself MHC. , 1999, Immunology today.
[3] Anajane G. Smith,et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.
[4] M. Gavin,et al. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. , 1998, Current opinion in hematology.
[5] J. Melo,et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. , 1998, Blood.
[6] J. Finke,et al. Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma , 1998, International journal of cancer.
[7] J. Dick,et al. A newly discovered class of human hematopoietic cells with SCID-repopulating activity , 1998, Nature Medicine.
[8] J. Falkenburg,et al. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Goldman,et al. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. , 1998, Blood.
[10] Y. Oji,et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. , 1998, Blood.
[11] J. Dick,et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. , 1998, Blood.
[12] D. Roopenian,et al. Much ado about minor histocompatibility antigens. , 1998, Immunology today.
[13] U. Gullberg,et al. Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program , 1998, Oncogene.
[14] J. Shabanowitz,et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. , 1998, Science.
[15] H. Stauss,et al. Generation of human tumor‐reactive cytotoxic T cells against peptides presented by non‐self HLA class I molecules , 1998, European journal of immunology.
[16] A. Barrett,et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. , 1997, Blood.
[17] T. Sugiyama,et al. WT1 contributes to leukemogenesis: Expression patterns in 7,12‐dimethylbenz[a]anthracene (DMBA)‐induced leukemia , 1997, International journal of cancer.
[18] U. Maurer,et al. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. , 1997, Experimental Hematology.
[19] C. Roberts,et al. Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[20] J. Dick,et al. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.
[21] P. Baird,et al. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. , 1997, Experimental hematology.
[22] Y. Sonoda,et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. , 1997, Blood.
[23] E. Sadovnikova,et al. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[24] T. Kudoh,et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. , 1996, Blood.
[25] P. Smith,et al. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. , 1996, Oncogene.
[26] J. Goldman,et al. Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] T. Akiyama,et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.
[28] E. Thiel,et al. Expression of the WT1 Wilms' tumor gene by normal and malignant human melanocytes , 1994, International journal of cancer.
[29] A. Tsukamoto,et al. Human fetal bone marrow early progenitors for T, B, and myeloid cells are found exclusively in the population expressing high levels of CD34. , 1994, Blood.
[30] A. Viel,et al. Molecular mechanisms possibly affecting WT1 function in human ovarian tumors , 1994, International journal of cancer.
[31] P. Parham,et al. The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. , 1992, Journal of immunology.
[32] J. Griffin,et al. Clonogenic cells in acute myeloblastic leukemia. , 1986, Blood.
[33] R. Demars,et al. Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. , 1984, Human immunology.
[34] E. McCulloch. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982) , 1983 .
[35] A. Palumbo,et al. Establishment of a Ph1-positive human cell line (BV173). , 1983, Journal of the National Cancer Institute.
[36] C. Alvarado,et al. Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes , 1982 .
[37] C. Lozzio,et al. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.
[38] A. Jochemsen,et al. The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? , 1998, International review of cytology.
[39] W. Wilmanns,et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.
[40] C. Alvarado,et al. Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes. , 1982, Blood.